Division of Cardiology, Department of Medicine, Sinai Health System, University of Toronto, Toronto, Canada.
The Centre for Women's and Infant's Health at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
Am J Physiol Heart Circ Physiol. 2020 Apr 1;318(4):H1008-H1017. doi: 10.1152/ajpheart.00109.2020. Epub 2020 Mar 20.
Circulating levels of placental growth factor (PlGF) are significantly reduced in women who develop preeclampsia. Low molecular weight heparin (LMWH) has been shown to acutely elevate circulating PlGF levels in pregnant women at increased risk of preeclampsia. The objective of the current investigation was to determine the mechanisms by which LMWH mediates the extracellular release of PlGF from endothelial cells. Cultured human aortic endothelial cells (HAECs) and human umbilical vein endothelial cells (HUVECs) were exposed to LMWH; PlGF transcription, translation, mobilization, and secretion were then assessed. LMWH significantly increased the release of PlGF from both HAECs and HUVECs. LMWH treatment promoted a significant increase of mRNA expression in HAECs, accompanied by the intracellular transport and release of PlGF into the conditioned media. LMWH-mediated release of PlGF from HAECs was not directly mediated by extracellular mobilization, synthesis, or stability of PlGF mRNA/protein. LMWH exposure promotes the release of PlGF from endothelial cells through the upregulation of mRNA expression. Stimulation of circulating PlGF levels by LMWH may be an important mechanism by which LMWH could reduce the risk of preeclampsia or minimize disease severity. There are few therapeutic options available for the prevention of preeclampsia, a serious hypertensive disorder of pregnancy. Women who subsequently develop preeclampsia exhibit significantly reduced circulating levels of the proangiogenic placental growth factor protein. Low molecular weight heparin (LMWH) has previously been investigated as a preventative therapy against the development of preeclampsia; however, its mechanism of action is not known. The current study determined that LMWH promotes the transcription and release of placental growth factor protein from endothelial cells, providing a mechanistic basis by which LMWH could reduce the risk of preeclampsia or minimize disease severity.
循环中的胎盘生长因子(PlGF)水平在发生子痫前期的女性中显著降低。低分子量肝素(LMWH)已被证明可在患有子痫前期风险增加的孕妇中急性升高循环 PlGF 水平。本研究的目的是确定 LMWH 介导内皮细胞释放外源性 PlGF 的机制。培养的人主动脉内皮细胞(HAEC)和人脐静脉内皮细胞(HUVEC)暴露于 LMWH;然后评估 PlGF 的转录、翻译、动员和分泌。LMWH 显著增加了 HAEC 和 HUVEC 中 PlGF 的释放。LMWH 处理显著增加了 HAEC 中的 mRNA 表达,同时将 PlGF 从细胞内转运并释放到条件培养基中。LMWH 介导的 HAEC 中 PlGF 的释放不是通过 PlGF mRNA/蛋白的细胞外动员、合成或稳定性直接介导的。LMWH 暴露通过上调 mRNA 表达促进内皮细胞中 PlGF 的释放。LMWH 刺激循环 PlGF 水平的增加可能是 LMWH 降低子痫前期风险或最小化疾病严重程度的重要机制。预防子痫前期的治疗选择很少,子痫前期是一种严重的妊娠高血压疾病。随后发生子痫前期的女性表现出明显降低的促血管生成胎盘生长因子蛋白的循环水平。低分子量肝素(LMWH)以前曾被研究作为预防子痫前期的治疗方法;然而,其作用机制尚不清楚。本研究确定 LMWH 可促进内皮细胞中胎盘生长因子蛋白的转录和释放,为 LMWH 降低子痫前期风险或最小化疾病严重程度提供了机制基础。